AI In Predictive Toxicology - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The aI in predictive toxicology market size is expected to grow from USD 0.80 billion in 2025 to USD 0.95 billion in 2026 and is forecast to reach USD 2.41 billion by 2031 at 20.42% CAGR over 2026-2031. This report is Segmented by Application (Early Discovery Triage & Design, and Others), End-User (Pharmaceutical & Biotechnology Companies, and Others), Technology (Machine Learning, and Others), Toxicity Endpoint (Genotoxicity/Mutagenicity, and Others), Deployment (Cloud/SaaS, On-Premise), and Geography (North America, Europe, and Others). The Market Forecasts are Provided in Terms of Value (USD).

Global AI In Predictive Toxicology Market Trends and Insights

ICH M7 And NAMs Accelerate in Silico Adoption

The 2025 ICH M7(R3) addendum consolidates nitrosamine risk assessment and formalizes expanded QSAR and read across methodologies that reinforce model informed impurity evaluations across submissions. Under this framework, model developers highlight standardized QMRF/QPRF reporting practices that document endpoints, algorithms, applicability domains, and validation, which helps establish traceable and fit for purpose QSAR evidence across the AI in predictive toxicology market. National guidance in the UK further endorses combining rule based systems with statistical models under expert oversight for genotoxicity predictions, which encourages blended approaches for Ames related decision making Data sharing and curated knowledge bases continue to grow through efforts like Lhasa Limited’s nitrosamine resources and Vitic Excipients, which support pre competitive exchanges that reduce duplication and improve reproducibility. Practical integration with medicinal chemistry environments, for example through Derek Nexus access within discovery decision platforms, allows teams to screen risk motifs during design and to prioritize safer series earlier. These elements together improve confidence in in silico evidence packages and increase the operational role of QSAR across the AI in predictive toxicology market.

FDA/EPA Shift Away from Animal Testing Spurs AI Tox

The FDA’s April 2025 roadmap sets a near term path to make animal studies the exception, which elevates the role of new approach methods and AI enabled models in regulatory decision support for the AI in predictive toxicology market. The FDA’s ISTAND pilot had accepted eight NAMs by early 2025 and continues to promote model credibility frameworks that emphasize data governance, lifecycle maintenance, and transparent documentation aligned with intended use. EPA’s ToxCast portfolio provides high throughput assay data and harmonized retrieval pipelines that are enabling reproducible ML workflows and consistent reporting formats for concentration-response modeling. This alignment is complemented by PBPK platforms licensed by multiple global regulators and enhanced with AI enabled features in 2026, which streamline model building and submission packages. As these policies propagate across the AI in predictive toxicology market, development teams are able to reduce reliance on long duration animal studies and redirect resources to model informed study design.

Sparse, Heterogeneous Labels for Complex Endpoints (DART, Chronic)

Developmental and reproductive toxicity and long latency endpoints remain hard to model because labeled datasets are fragmented and uneven across species and assay types, which limits generalization outside training domains. While public programs expanded chemical coverage and increased the number of high throughput assays, many complex endpoints still have data scarcity that constrains balanced performance and reduces external validity. Combined modeling approaches that integrate multiple assay features show improvements on curated sets for developmental toxicity, but the limited compound counts emphasize the need for sustained data generation. Heterogeneous assay protocols and species differences introduce harmonization challenges that require additional metadata standards and guardrails for model transfer. Addressing these constraints will require further investment in public datasets and stronger cross industry sharing to unlock robust models for DART and chronic endpoints in the AI in predictive toxicology market.

Other drivers and restraints analyzed in the detailed report include:

• Open Toxicology Datasets (ToxCast/Tox21) Enable ML Workflows
• Pharma Needs to Cut Attrition and Timelines to Boost AI Tox
• Regulatory Acceptance Still Narrow Beyond ICH M7/CiPA

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Early Discovery Triage and Design accounted for 49.41% of the AI in predictive toxicology market size in 2025 as R&D teams scaled virtual screening and design space exploration before synthesis. Generative design workflows report faster design cycles with lower synthesis counts, which helps reduce costs during hit to lead and lead optimization. Platform integrations that surface toxicity alerts inside medicinal chemistry tools help scientists avoid risky substructures and prioritize safer series earlier in cycles. Curated nitrosamine resources and impurity frameworks enable consistent decision support for impurity control strategies in regulated submissions. Expanded programmatic access to high throughput screening data continues to provide training corpora and benchmarking sets for discovery stage classification and prioritization across the AI in predictive toxicology market.

Preclinical Safety Assessment is forecast to grow at 22.61% CAGR from 2026 to 2031 as model informed DILI prediction and virtual trial simulations compress assay timelines and focus confirmatory testing. Commercial DILI modules that achieve strong predictive performance are being embedded into broader translational platforms, which standardizes feature extraction and case review. In silico cardiac risk tools complement wet lab ion channel assays by aggregating multi channel effects and delivering clear risk classifications for study design. PBPK platforms with AI enabled guidance and chat support reduce manual steps and accelerate scenario testing for formulation and DDI risk. Public funding for high throughput genetic toxicology and collaborative datasets is also expanding access to transcriptomic information that complements conventional preclinical endpoints.

Pharmaceutical and Biotechnology Companies commanded 47.43% of revenue in 2025 as internal platforms scaled ML guided design, safety triage, and PBPK workflows across discovery and early development. Enterprise programs in 2026 highlight internal foundation models that forecast compound behavior and identify likely off target effects to de risk earlier. Partnerships that combine knowledge graphs and multimodal biomedical data with pharmaceutical domain expertise continue to expand, which supports target discovery and mechanistic annotation. Early deployment examples show design acceleration and synthesis reduction with generative platforms, which helps conserve resources in high throughput ideation settings. Broader access to NAMs and standardized QSAR reporting supports consistent internal governance for submission ready evidence packets across the AI in predictive toxicology market.

Cpntract Research Organizations (CROs) and Consultancies are expected to grow at 21.13% CAGR as sponsors outsource AI enabled screening, QSAR reporting, and preclinical simulations to partners that operate at scale. Service providers are launching AI driven discovery platforms trained on proprietary assay archives to improve ADMET classification performance and provide consistent reporting at enterprise scale. Strategic collaborations that link AI with clinical and preclinical expertise continue to expand the service scope for sponsors seeking end to end coverage. Public awards to build NAM based toxicity models are supporting ecosystem capacity by funding data assets and shared tools for DILI and cardiotoxicity across networks of academic and biopharma collaborators. As sponsors seek flexible capacity and specialized capabilities, CROs are integrating cloud based analytics and model libraries to shorten turnaround times and support compliance in the AI in predictive toxicology market.

Complete Report Scope:

• By Application
  • Early Discovery Triage and Design
  • Preclinical Safety Assessment
  • Regulatory Compliance Dossiers
  • Consumer Products and Cosmetics Safety
  • Others
• By End-user
  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations (CROs) and Consultancies
  • Cosmetics and Personal Care
  • Others
• By Technology
  • Machine Learning
  • Natural Language Processing
  • Others
• By Toxicity Endpoint
  • Genotoxicity / Mutagenicity
  • Carcinogenicity
  • Cardiotoxicity
  • Dermal Sensitization and Irritation
  • Neurotoxicity
  • Others
• By Deployment
  • Cloud / SaaS
  • On-Premise
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 48.67% of the AI in predictive toxicology market size in 2025 as the FDA roadmap shifted the center of gravity toward NAM adoption and model informed planning across preclinical programs. The region’s policy signals and pilot qualifications support stepwise validation and model credibility frameworks that foster investment in in silico tools. Public funding for model based cardiac and liver safety is expanding infrastructure and datasets through consortium awards and collaborative development programs. Government portfolios also advance high throughput genetic toxicology capabilities that can be leveraged by ML pipelines to augment classification performance and mechanistic inference in the AI in predictive toxicology market. These elements combine with cloud PBPK platforms licensed by multiple agencies to streamline model development and submission ready reporting.

Europe held a significant share in 2025 and continues to emphasize standardized QSAR reporting, expert review of out of domain predictions, and knowledge based justification as part of case specific assessments. Collaborative initiatives on read across and mechanistic frameworks in the literature support convergence across agencies and help developers prepare more transparent dossiers. Northern European regulators also leverage regional QSAR databases in plant protection assessments, which reinforces the practical value of shared tools and harmonized practices. Pre competitive databases and tooling from companies headquartered in the region help reduce duplication and enable consistent re use of curated results across programs in the AI in predictive toxicology market. Expanded access to open QSAR suites across European labs complements this foundation and continues to broaden standard practice.

Asia Pacific is the fastest growing region through 2031 with a 24.33% CAGR as sponsors and CROs increase adoption of model informed approaches and cloud based analytics for safety triage and study design. Laboratories in the region continue to integrate public high throughput datasets and open QSAR tools that support scalable ML pipelines for screening and prioritization. Growth in AI enabled design and simulation platforms also supports distributed collaboration across discovery and preclinical workflows within the AI in predictive toxicology market. As regional R&D footprints expand, hybrid deployment models help maintain data sovereignty while accessing elastic compute for training and scenario analysis. Over the forecast period, the combination of public datasets, vendor platform maturity, and regional capacity building will continue to underpin strong adoption curves across Asia Pacific.

List of Companies Covered in this Report:

• ACD/Labs
• Benevolent AI
• Certara
• Charles River
• ChemAxon
• Clarivate (Cortellis)
• Dassault Systemes BIOVIA
• Eurofins
• Evotec
• Exscientia
• IDEAconsult
• Inotiv
• InSilicoTrials
• Instem (Leadscope)
• LabCorp
• Lhasa Limited
• MultiCASE
• Optibrium
• QSAR Lab
• Simulations Plus

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support